Tailored priming of pancreatic cancer progression and metastatic targeting using KD025, a phase II (ROCK2) inhibitor: fine-tuning treatment via single cell intravital imaging

使用 II 期 (ROCK2) 抑制剂 KD025 定制胰腺癌进展和转移靶向启动：通过单细胞活体成像微调治疗

• 批准号: nhmrc : GNT1160022
• 金额: $ 89.24万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/tailored-priming-pancreatic-intravital-imaging/1379105
• 关键词: Tailored; priming; pancreatic; cancer; progression

Inefficient drug response in solid tumour tissue is commonly a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug targeting in order to improve the encouraging anti-cancer profile of the new drug combination Gemcitabine/Abraxane in pancreatic cancer.

实体肿瘤组织中的低效药物反应通常是癌症治疗临床有效性的限制因素。使用尖端成像技术和模拟这种疾病的3D模型，我们已经绘制了肿瘤不同区域内药物反应差的区域。在这里，我们精准并特别针对限制有效药物靶向的关键因素，以改善新药吉西他滨/阿布拉沙尼联合治疗胰腺癌令人鼓舞的抗癌效果。